Lumakras A Big Focus For Amgen; More Data Coming Soon
KRAS Inhibitor’s Q2 Sales Lumped In With ‘Other’ Products
Amgen reported 5% year-over-year revenue growth to $6.5bn in the second quarter, up 11% from Q1. It did not break out Lumakras sales but detailed upcoming data that may support future indications.
